Invivyd Quote - IVVD

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.60

Bid

0.584

Ask

0.62

Volume

403

0.00 Day's Range 0.00

0.57 52 Week Range 5.195

Market Cap

71.77M

Previous Close

0.584

Open

Last Trade

215

0.6

(formt)

Last Trade Time

06:00:16

Financial Volume

VWAP

Average Volume (3m)

557,943

Shares Outstanding

119,616,035

Dividend Yield

PE Ratio

-0.35

Earnings Per Share (EPS)

-1.66

Revenue

Net Profit

-198.64M

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

invivyd.com

Headquarters

Wilmington, Delaware, USA

Founded

Invivyd Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IVVD. The last closing price for Invivyd was US$0.58. Over the last year, Invivyd shares have traded in a share price range of US$ 0.57 to US$ 5.195.

Invivyd currently has 119,616,035 shares outstanding. The market capitalization of Invivyd is US$69.86 million. Invivyd has a price to earnings ratio (PE ratio) of -0.35.

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing...

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve...

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0356	-5.60100692259	0.6356	0.654	0.57	809093	0.58431221	CS
4	-0.26	-30.2325581395	0.86	0.86	0.57	876783	0.67435892	CS
12	-0.6201	-50.8237029752	1.2201	1.27	0.57	557943	0.83324435	CS
26	-1.03	-63.1901840491	1.63	1.8	0.57	579397	0.98482652	CS
52	-1.1	-64.7058823529	1.7	5.195	0.57	920724	2.74895021	CS
156	-4.1	-87.2340425532	4.7	5.195	0.57	559381	2.53412368	CS
260	-4.1	-87.2340425532	4.7	5.195	0.57	559381	2.53412368	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PALIPalisade Bio Inc	US$ 3.20 (128.57%)	20.1M
SYTASiyata Mobile Inc	US$ 1.05 (40.37%)	12.24M
TRVITrevi Therapeutics Inc	US$ 3.40 (36.55%)	2.47M
ZENAZenaTech Inc	US$ 7.46 (31.11%)	3.6M
ATLNAtlantic International Corporation	US$ 7.00 (22.74%)	1
KROSKeros Therapeutics Inc	US$ 18.78 (-72.64%)	609.66k
SPGCSacks Parente Golf Inc	US$ 0.50 (-64.29%)	163.73k
PNBKPatriot National Bancorp Inc	US$ 1.08 (-58.78%)	16
AVGRAvinger Inc	US$ 0.441 (-46.22%)	87.3k
HEPAHepion Pharmaceuticals Inc	US$ 0.36 (-38.46%)	1
PALIPalisade Bio Inc	US$ 3.20 (128.57%)	20.1M
CDTConduit Pharmaceuticals Inc	US$ 0.1012 (14.61%)	14.2M
AMPGAmplitech Group Inc	US$ 2.20 (13.99%)	13.48M
SYTASiyata Mobile Inc	US$ 1.05 (40.37%)	12.24M
LAESSEALSQ Corporation	US$ 1.245 (8.26%)	8.74M